Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 102Lymphoma, Large B-Cell, Diffuse 32Neoplasms 22Lymphoma, Non-Hodgkin 20Lymphoma, Follicular 20Lymphoma 19Multiple Myeloma 15Lymphoma, B-Cell 11Neoplasm Metastasis 10Recurrence 8Lymphoma, T-Cell, Peripheral 7Prostatic Neoplasms, Castration-Resistant 5Prostate Cancer Metastatic 5Metastatic Castration-resistant Prostate Cancer 5Lymphoma, Mantle-Cell 5Hematologic Diseases 5Lymphoma, B-Cell, Marginal Zone 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Metastatic Castration-Resistant Prostate Cancer 3Leukemia, Lymphocytic, Chronic, B-Cell 3Triple Negative Breast Neoplasms 2Pain 2Metastatic Castration Resistant Prostate Cancer 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphatic Diseases 2Leukemia 2Graft vs Host Disease 2Endometrial Neoplasms 2

Interventions

enzalutamide 14Docetaxel 7radium Ra 223 dichloride 6Abiraterone Acetate 6Prednisone 5darolutamide 4abiraterone 3olaparib 2niraparib 2atezolizumab 2apalutamide 2zimberelimab 1xentuzumab 1tasquinimod 1sacituzumab govitecan 1sabizabulin 1quemliclustat 1ipatasertib 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1Rosuvastatin Calcium 1Radium-223 1Pluvicto 1Pioglitazone 1Nivolumab 1JNJ-64619178 1JNJ-64264681 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms, Castration-Resistant × Prednisone × Clear all
NCT06353386 2026-05-26

MK-5684-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05848011 2026-05-22

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

MacroGenics

Phase 2 Completed
154 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03431350 2026-05-11

QUEST

Janssen Research & Development, LLC

Phase 2 Active not recruiting
136 enrolled 29 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT07225946 2026-05-11

KLK2-PASenger

Janssen Research & Development, LLC

Phase 3 Recruiting
800 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03748641 2026-05-08

MAGNITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
765 enrolled 16 charts 1 FDA
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡